140 related articles for article (PubMed ID: 2783561)
1. Decrease in interleukin 2-induced vascular leakage in the lungs of mice by administration of recombinant interleukin 1 alpha in vivo.
Puri RK; Travis WD; Rosenberg SA
Cancer Res; 1989 Feb; 49(4):969-76. PubMed ID: 2783561
[TBL] [Abstract][Full Text] [Related]
2. In vivo administration of interferon alpha and interleukin 2 induces proliferation of lymphoid cells in the organs of mice.
Puri RK; Travis WD; Rosenberg SA
Cancer Res; 1990 Sep; 50(17):5543-50. PubMed ID: 2386960
[TBL] [Abstract][Full Text] [Related]
3. Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2.
Rosenstein M; Ettinghausen SE; Rosenberg SA
J Immunol; 1986 Sep; 137(5):1735-42. PubMed ID: 3528289
[TBL] [Abstract][Full Text] [Related]
4. Histamine improves survival and protects against interleukin-2-induced pulmonary vascular leak syndrome in mice.
Hornyak SC; Orentas DM; Karavodin LM; Gehlsen KR
Vascul Pharmacol; 2005 Mar; 42(4):187-93. PubMed ID: 15820445
[TBL] [Abstract][Full Text] [Related]
5. Combined effects of interferon alpha and interleukin 2 on the induction of a vascular leak syndrome in mice.
Puri RK; Rosenberg SA
Cancer Immunol Immunother; 1989; 28(4):267-74. PubMed ID: 2495179
[TBL] [Abstract][Full Text] [Related]
6. Recombinant interleukin 2 stimulates in vivo proliferation of adoptively transferred lymphokine-activated killer (LAK) cells.
Ettinghausen SE; Lipford EH; Mulé JJ; Rosenberg SA
J Immunol; 1985 Nov; 135(5):3623-35. PubMed ID: 3900213
[TBL] [Abstract][Full Text] [Related]
7. IL-1 receptor antagonist (IL-1ra) augments IL-2-induced pulmonary vascular leak.
Thom AK; Fraker DL; Norton JA
J Surg Res; 1993 Apr; 54(4):336-41. PubMed ID: 8331927
[TBL] [Abstract][Full Text] [Related]
8. Attenuation of interleukin 2-induced pulmonary vascular leak syndrome by low doses of oral methotrexate.
DeJoy SQ; Jeyaseelan R; Torley LW; Schow SR; Wick MM; Kerwar SS
Cancer Res; 1995 Nov; 55(21):4929-35. PubMed ID: 7585532
[TBL] [Abstract][Full Text] [Related]
9. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
Papa MZ; Mulé JJ; Rosenberg SA
Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
[TBL] [Abstract][Full Text] [Related]
10. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
Mulé JJ; Ettinghausen SE; Spiess PJ; Shu S; Rosenberg SA
Cancer Res; 1986 Feb; 46(2):676-83. PubMed ID: 3484431
[TBL] [Abstract][Full Text] [Related]
11. Evidence for the involvement of CD44 in endothelial cell injury and induction of vascular leak syndrome by IL-2.
Rafi-Janajreh AQ; Chen D; Schmits R; Mak TW; Grayson RL; Sponenberg DP; Nagarkatti M; Nagarkatti PS
J Immunol; 1999 Aug; 163(3):1619-27. PubMed ID: 10415067
[TBL] [Abstract][Full Text] [Related]
12. Increased vascular permeability in organs mediated by the systemic administration of lymphokine-activated killer cells and recombinant interleukin-2 in mice.
Ettinghausen SE; Puri RK; Rosenberg SA
J Natl Cancer Inst; 1988 Apr; 80(3):177-88. PubMed ID: 3258039
[TBL] [Abstract][Full Text] [Related]
13. Evidence for the involvement of Fas ligand and perforin in the induction of vascular leak syndrome.
Rafi AQ; Zeytun A; Bradley MJ; Sponenberg DP; Grayson RL; Nagarkatti M; Nagarkatti PS
J Immunol; 1998 Sep; 161(6):3077-86. PubMed ID: 9743374
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of murine renal carcinoma pulmonary metastases by systemic administration of interferon gamma: mechanism of action and potential for combination with interleukin 4.
Hillman GG; Younes E; Visscher D; Hamzavi F; Kim S; Lam JS; Montecillo EJ; Ali E; Pontes JE; Puri RK; Haas GP
Clin Cancer Res; 1997 Oct; 3(10):1799-806. PubMed ID: 9815566
[TBL] [Abstract][Full Text] [Related]
15. Interleukin 1 alpha and gamma-interferon induction of nitric oxide production from murine tumor-derived endothelial cells.
Chang MJ; Modzelewski RA; Russell DM; Johnson CS
Cancer Res; 1996 Feb; 56(4):886-91. PubMed ID: 8631029
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-1 alpha reduces the severity of the vascular leak syndrome produced by interleukin-2 and interleukin-2 plus interferon-alpha.
Fujita S; Puri R; Yu ZX; Travis W; Yamaguchi M; Ferrans VJ
Toxicol Pathol; 1994; 22(4):381-97. PubMed ID: 7817127
[TBL] [Abstract][Full Text] [Related]
17. Interleukin 1-induced augmentation of experimental metastases from a human melanoma in nude mice.
Giavazzi R; Garofalo A; Bani MR; Abbate M; Ghezzi P; Boraschi D; Mantovani A; Dejana E
Cancer Res; 1990 Aug; 50(15):4771-5. PubMed ID: 2196116
[TBL] [Abstract][Full Text] [Related]
18. IL-1 and IFN-gamma increase vascular permeability.
Martin S; Maruta K; Burkart V; Gillis S; Kolb H
Immunology; 1988 Jun; 64(2):301-5. PubMed ID: 3134297
[TBL] [Abstract][Full Text] [Related]
19. The role of active inducible nitric oxide synthase expression in the pathogenesis of capillary leak syndrome resulting from interleukin-2 therapy in mice.
Orucevic A; Hearn S; Lala PK
Lab Invest; 1997 Jan; 76(1):53-65. PubMed ID: 9010449
[TBL] [Abstract][Full Text] [Related]
20. Synergistic antitumor effects of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid alpha-interferon in the treatment of established murine hepatic metastases.
Cameron RB; McIntosh JK; Rosenberg SA
Cancer Res; 1988 Oct; 48(20):5810-7. PubMed ID: 3262413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
